Member Info for technick

big trades from earlier coming through...

if you take a 5x multiple on sales then current market cap of £50m is supported by sales of £10m... but as others are posting orders already in the range of £90m it does support a £1bn market cap. Not saying that's what we are worth by any stretch, but it shows todays cap is conservative in my view.

Interesting that the spreader shares seem now to have gone into general circulation and not taken up by any of the institutional holders, that bodes well for liquidity.... perhaps?

distribution agreement or sale in my opinion, CE-IVD in 3 weeks so will come later than the next rns

buys significantly above the ask, tick up coming

Can't be too many 'sell on news' shares about now... tick up coming

Any thoughts on options for Genedrive going forward

1. Sell and distribute plate test via Cytiva or another partner
2. Sell plate test to Cytiva and focus on POC finding separate distributors for Genedrive
3. Sell the whole business

Interesting options for Genedrive going forward here!

@weathergeek its been a mad year

based on todays early trades I suspect this will rise throughout the day to the £1.50 mark, can't buy but can sell...

right numbers just not in the right order, back to front!

no chance

where will this go today, on balance we should be similar MC to Novacyt now considering our global reach and not simply a UK focus

huge world wide orders coming via Cytiva, watch this space!

@scart I imagine that the little bead you see in the LinkedIn photo just pops into the Genedrive cartridge, I don't think its far behind!

The Genedrive® 96 SARS-CoV-2 assay combines genedrive's PCR chemistry integrated with Cytiva's LyoStable® stabilisation technology. The combination delivers several key competitive advantages to the genedrive test compared to the liquid, kit-based assays already on market. The Genedrive® 96 SARS-CoV2-test is a final format test which only requires the addition of patient sample, with no other user preparation required. Integrated controls within each test give confidence to the user that the input sample is of good quality, and the integrity of each reaction mix is confirmed with another internal standard. The temperature-stable nature of lyophilisation technology means that the test can be transported globally without the need for refrigeration, which will support global product distribution.

Before the announcement there was risk the product could not be made, we now know it can so the risk around availability is gone. A significant milestone.

If the NVCT £90m+ contract orders are replicated then north of £200m MC is completely possible. Testing is going to be around for a long time, also companies that can respond to the next outbreaks. Genedrive in an excellent position both on chemistry and also platform.

... this is only the start, we have the test on Genedrive to come! So what if GE were to buy the 96 test from Genedrive, £100m, £200m? Would that make sense? Or could they buy the whole business! I really think something like that could happen

Loving these Friday RNS’s! This really does put Genedrive into a commanding position. Production scale, completed assay, CE IVD registration underway, global sales and distribution partner tbc. Where will this go today? Those who sold yesterday presumably happy to take profit, now we can launch from this new base. Where will the share price end up today and early next week?

Well here we go!